Co-Authors
This is a "connection" page, showing publications co-authored by YILING LU and MICHAEL A DAVIES.
Connection Strength
0.326
-
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010 Feb; 9(2):257-67.
Score: 0.090
-
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020 12 14; 38(6):829-843.e4.
Score: 0.047
-
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998 Dec 01; 58(23):5285-90.
Score: 0.041
-
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239.
Score: 0.036
-
Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. 2015 Mar 15; 31(6):912-8.
Score: 0.031
-
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics. 2010 Dec; 6(4):129-51.
Score: 0.024
-
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One. 2010 Mar 26; 5(3):e9910.
Score: 0.023
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
Score: 0.022
-
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002 Apr 04; 21(15):2357-64.
Score: 0.013